Public Health England Microbiology Services Bristol, Bristol Royal Infirmary, Bristol, UK; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Infirmary, Bristol, UK.
Public Health England Microbiology Services Bristol, Bristol Royal Infirmary, Bristol, UK; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Infirmary, Bristol, UK; School of Clinical Sciences, University of Bristol, Bristol, UK.
Int J Antimicrob Agents. 2020 Sep;56(3):106076. doi: 10.1016/j.ijantimicag.2020.106076. Epub 2020 Jul 3.
Although cellulitis is a relatively common condition, there is uncertainty about the benefit of intravenous (IV) over oral (PO) antibiotic therapy, and the appropriate duration of treatment.
Data extracted from a clinical trial (NCT01876628) of antibiotic therapy for cellulitis were used to assess the association between the route of administration and duration of treatment, and clinical outcome.
Of 323 patients with antibiotic data, 114 received some IV therapy. IV antibiotic therapy was preferred in those who had received antibiotics prior to trial entry (P < 0.001). Patients characterised as having more severe cellulitis (C-reactive protein > 100 mg/L, affected skin surface area > 5% or systemic inflammatory response syndrome score ≥ 1) were more likely to have had IV therapy. Those given only PO therapy were more likely to have improved at day 5 compared with those given at least a single dose of IV therapy (P = 0.015), and were as likely to be back to their normal activities at day 10 (P = 0.90), and day 30 (P = 0.86). There was no association between initial severity and the duration of antibiotic therapy given within the trial. There was no association between duration of antibiotic therapy and outcome as measured at day 10 and day 30.
This study provides evidence that recovery is not associated with the route of antibiotic administration for patients with cellulitis of similar severity, or that a course length of > 5 days results in any additional benefit.
虽然蜂窝织炎是一种相对常见的疾病,但对于静脉(IV)与口服(PO)抗生素治疗的益处以及治疗的适当持续时间仍存在不确定性。
从一项蜂窝织炎抗生素治疗临床试验(NCT01876628)中提取的数据用于评估给药途径和治疗持续时间与临床结果之间的关联。
在具有抗生素数据的 323 名患者中,有 114 名接受了一些 IV 治疗。在试验入组前接受过抗生素治疗的患者(P<0.001)更倾向于接受 IV 抗生素治疗。具有更严重蜂窝织炎(C 反应蛋白>100mg/L,受累皮肤表面积>5%或全身炎症反应综合征评分≥1)特征的患者更有可能接受 IV 治疗。与接受至少一剂 IV 治疗的患者相比,仅接受 PO 治疗的患者在第 5 天更有可能改善(P=0.015),并且在第 10 天(P=0.90)和第 30 天(P=0.86)恢复正常活动的可能性相同。在试验中给予的抗生素治疗的初始严重程度与持续时间之间没有关联。抗生素治疗的持续时间与第 10 天和第 30 天的测量结果之间没有关联。
本研究提供了证据表明,对于严重程度相似的蜂窝织炎患者,恢复情况与抗生素给药途径无关,或者>5 天的疗程不会带来任何额外的益处。